Geoffrey R. Weiss, MD
Clinical trials with targeted therapies and cytokines
Geoffrey R. Weiss, M.D., Chief of the Division of Hematology-Oncology and Deputy Director of the Cancer Center for Clinical Research and Clinical Affairs, is a medical oncologist and clinical investigator. During his previous appointment at the University of Texas Health Science Center at San Antonio, Dr. Weiss was an investigator of the Institute for Drug Development and contributed to the clinical advance of 40 new anticancer agents. Dr. Weiss has devoted much of his investigational career to the development of new therapies for genitourinary malignancies and for malignant melanoma. Since 1986, he has been a member of the Cytokine Working Group, a multi-institution clinical research consortium dedicated to the evaluation of cytokine-based therapies of renal cell carcinoma and malignant melanoma. This Group has been central to the development of high-dose interleukin-2 as an FDA-approved therapy of renal cell carcinoma and malignant melanoma.
Dr. Weiss joined the University of Virginia Cancer Center in November 2004. He is a member of the faculty of the Human Immune Therapy Center (HITC) and participates in the clinical trials of synthetic peptide vaccines for malignant melanoma. He has opened a clinical program utilizing high-dose interleukin-2 for the treatment of renal cell carcinoma and malignant melanoma, a resource soon to be applied to clinical trials of the Cytokine Working Group. Dr. Weiss envisions creating investigator-initiated clinical trials within the HITC developing cytokine therapies as adjuncts to vaccine trials and exploring targeted therapies combined with immune therapies of cancer.